Trial reportNeurology2014
Allopregnanolone levels and seizure frequency in progesterone-treated women with epilepsy.
Trial report in Neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- A scoping review of hormonal clinical trials in menstrual cycle-related brain disorders: Studies in premenstrual mood disorder, menstrual migraine, and catamenial epilepsy.Frontiers in neuroendocrinology · 2023Pooled it
- Treatments for seizures in catamenial (menstrual-related) epilepsy.The Cochrane database of systematic reviews · 2021Pooled it
- Neurosteroids and Seizure Activity.Frontiers in endocrinology · 2020Pooled it
- Scientific Symposium: Biological Sex as a Factor in Epilepsy Research and Treatment.Epilepsy currents · 2026Article
- Low-dose combination of ultramicronized palmitoylethanolamide and docosahexaenoic acid on neurosteroid and neuroinflammatory dysregulation in autism spectrum disorders.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- Metformin as a Neuroendocrine Modulator in Catamenial Epilepsy: Interplay with Sex Hormones and Neurosteroids.Molecular neurobiology · 2025Review
- The neuroendocrine puzzle of epilepsy and infertility: what are we missing?Frontiers in neurology · 2025Review
- Benzodiazepines for the Treatment of Seizure Clusters.CNS drugs · 2024Review
- Insights into neurosteroids and their role in women with epilepsy.Frontiers in global women's health · 2024Review
- Trajectories of Allopregnanolone and Allopregnanolone to Progesterone Ratio across the Six Subphases of Menstrual Cycle.Biomolecules · 2023Article
- Review
- [Epilepsy with catamenial pattern].Revista de neurologia · 2022Review
- Neurosteroid replacement therapy for catamenial epilepsy, postpartum depression and neuroendocrine disorders in women.Journal of neuroendocrinology · 2022Review
- Article
- Sleep Disruption Worsens Seizures: Neuroinflammation as a Potential Mechanistic Link.International journal of molecular sciences · 2021Review
- Pregnant women with more seizures have lower allopregnanolone concentrations.Epilepsy research · 2021Article
- Effects of the Menstrual Cycle on Neurological Disorders.Current neurology and neuroscience reports · 2021Review
- Treatments for seizures in catamenial (menstrual-related) epilepsy.The Cochrane database of systematic reviews · 2019Review
- Neurosteroid regulation of GABABrain research · 2019Review
- Neurosteroid Actions in Memory and Neurologic/Neuropsychiatric Disorders.Frontiers in endocrinology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo determine whether allopregnanolone (AP) may mediate seizure reduction in progesterone-treated women with epilepsy.
methodsThe NIH Progesterone Trial compared the efficacy of adjunctive cyclic natural progesterone therapy vs placebo treatment of intractable seizures in 294 subjects, randomized 2:1 to progesterone or placebo, stratified by catamenial vs noncatamenial designation. Treatments were compared on proportions of 50% responders, and changes in seizure frequency from 3 baseline to 3 treatment cycles. Serum AP levels were measured by radioimmunoassay from 155 women with intractable focal-onset seizures who had baseline and treatment-phase midluteal serum samples drawn each cycle for hormone measurements.
resultsThere was no significant correlation between percentage changes in AP levels and seizure frequencies from baseline to treatment for either the catamenial or noncatamenial stratum. There was a significant correlation for the subset of subjects who showed a significantly greater responder rate in the post hoc analysis of the trial, i.e., subjects who had a 3-fold or greater increase in average daily seizure frequency perimenstrually compared with the midfollicular and midluteal phases (C1 ≥ 3: r = -0.442, p = 0.013, and specifically for C1 ≥ 3 progesterone-treated subjects [r = -0.452, p = 0.035], but not other groups [C1 ≥ 3 placebo: r = -0.367; C1 <3 progesterone: r = 0.099; C1 <3 placebo: r = 0.131; p = not significant]).
conclusionsThe findings support AP as a mediator of seizure reduction in progesterone-treated women who have a substantial level of perimenstrually exacerbated seizures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.